XENE
Market read
The latest filing evidence is available. 0 of 2 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.
Invalidation: The isolated read changes if XENE's group or a disclosed connection begins moving with it.
Research brief
The latest filing evidence is available. 0 of 2 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.
No thresholded supportive filing evidence is available yet.
Company research
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
No qualifying supportive evidence was identified.
Reported annual revenue and per-share history. This is accounting history, not a forecast.
What management says matters
“The foreign exchange gain decreased by $2.0 million and $1.5 million for the three and six months ended June 30, 2026, respectively, due to fluctuations in the value of the Canadian dollar, partially offset by a lower balance of cash and cash equivalents and…”10-Q · Aug 6, 2026 ↗
“The increase in cash used in operating activities was primarily driven by higher research and development and general and administrative expenses, no revenue recognized in the six months ended June 30, 2026, lower cash received from interest income, and chang…”10-Q · Aug 6, 2026 ↗
Valuation discipline
Price/sales 621.8× · EV/sales 595.2×. Comparisons use only industry-matched filing peers.
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
Jodie has not returned a relevant primary source or news item for XENE. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Latest filing assessment
10-Q filed 2026-08-06 against the comparable filing from 2025-08-11.
Capital and cash conversion
Capex, revenue, and operating cash flow are matched to the same reported duration. Reported accounting context, not a forecast or trading recommendation.
No thresholded improvement was identified.
“2025 2026 2025 Increase/(Decrease) 2026 2025 Increase/(Decrease) Direct external costs: Azetukalner $ 55,760 $ 43,405 $ 12,355 $ 102,833 $ 74,906 $ 27,927 Pain programs 5,582 925 4,657 9,973 1,977 7,996 Pre-clinical, discovery and other programs 4,683 5,186 (503 ) 7,641 9,101 (1,460 ) Indirect costs: Personnel-related (including stock-based compensation) 28,557 22,869 5,688 58,442 44,176 14,266 Other unallocated expenses 4,642 2,600 2,042 8,843 6,025 2,818 Research and development expenses $ 99,224 $ 74,985 $ 24,239 $ 187,732 $ 136,185 $ 51,547 Direct external costs related to azetukalner increased by $12.4 million and $27.9 million for the three months and six months ended June 30, 2026, r...”
“39 $ 187,732 $ 136,185 $ 51,547 Direct external costs related to azetukalner increased by $12.4 million and $27.9 million for the three months and six months ended June 30, 2026, respectively, primarily due to our ongoing Phase 3 clinical studies in the MDD and BPD programs, as well as manufacturing activities to support our planned NDA submission.”
“Pain programs costs increased by $4.7 million and $8.0 million for the three months and six months ended June 30, 2026, respectively, primarily due to our ongoing Phase 1 clinical studies of XEN1701 and XEN1120, as well as manufacturing activities to support the clinical studies.”
Historical filing backfill generated after the original filing window. It is not part of Jodie's live track record.
Business ecosystem
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
“Our Partnered Program with Neurocrine Biosciences In December 2019, we entered into a license and collaboration agreement with Neurocrine Biosciences to develop treatments for epilepsy.”
“There are other ASMs in development that could potentially compete with our products, including product candidates in development from Biohaven Ltd., Jazz Pharmaceuticals, plc, Neurona Therapeutics Inc., NeuShen Therapeutics, Inc., Otsuka Pharmaceutical Co.”
Depended on by
“Some of our other collaborators include Nxera Pharma UK Limited (formerly Sosei Heptares), Takeda Pharmaceutical Company Limited, Voyager Therapeutics, Inc., and Xenon Pharmaceuticals Inc.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
XENE is currently a Leader in the organic co-movement group Biotechnology Stocks. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
Context history
No durable theme membership has been observed for this name yet.